Previous studies have reported that 4-1BBL-expressing tumor vaccine in combination with CTLA-4 blockade was effective in reducing tumor incidence and increasing in the survival of C57BL/6 mice transplanted subcutaneously with prostate cancer RM-1 cells (Youlin et al., 2012). The gene discussed is CTLA4; the disease is prostate carcinoma.